US 9765340
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders
granted A61KA61K31/7088
Quick answer
US patent 9765340 (RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders) held by Arrowhead Pharmaceuticals, Inc. expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K31/7088